Home > Neurology > EAN 2019 > Multiple Sclerosis > Randomised and observational studies comparing treatments

Randomised and observational studies comparing treatments

Presented By
Prof. Giancarlo Comi, Vita-Salute San Raffaele University, Italy
EAN 2019
In two randomised phase 3 studies, SUNBEAM and RADIANCE, ozanimod reduced whole brain volume loss (BVL), cortical grey matter volume, and thalamic volume in relapsing MS patients compared with IFN-beta-1a [1]. In two other studies comparing MS treatments, there was no difference in long-term efficacy of IFN and azathioprine [2], while in another study resting state functional connectivity was significantly increased in both fingolimod- and natalizumab-treated relapsing-remitting MS patients [3]. In the SUNBEAM and RADIANCE studies, participants received oral ozanimod hydrochloride 1 or 0.5 mg/day or intramuscular IFN beta-1a 30 µg a week for ≥12 months (SUNBEAM; n=1,346) or 24 months (RADIANCE; n=1,313). The effects on the whole BVL were presented by Prof. Giancarlo Comi (Vita-Salute San Raffaele University, Italy) [1]. After 12 months in SUNBEAM, whole BVL was -0.61, -0.49, and -0.41 in the IFN-beta-1a, ozanimod 0.5 mg, and ozanimod 1 mg group, respective...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on